Navigation Links
ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer
Date:10/28/2011

ALIMTA® (pemetrexed for injection), Lilly

Indications and Important Safety Information

Indications

ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is approved by the FDA for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is approved by the FDA as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, after prior chemotherapy. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is a treatment for malignant pleural mesothelioma (MPM), which is a cancer that affects the inside lining of the chest cavity. ALIMTA is given with cisplatin, another anticancer medicine (chemotherapy), when surgery is not an option.

Important Safety Information for ALIMTA® (pemetrexed for injection)

What is the most important information that I should know about ALIMTA?

ALIMTA can suppress bone marrow function, which may cause low blood cell counts.

ALIMTA may not be appropriate for some patients.

If you are allergic to ALIMTA, tell your doctor because you should not receive it.

If you have liver or kidney problems, be sure to tell your doctor. Your dose of ALIMTA may have to be changed, or ALIMTA may not be right for you.

Your doctor will prescribe a medicine called a "corticosteroid" to take for 3 days during e
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
2. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
3. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
4. Lung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta®
5. ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer
6. ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... and SOUTH SAN FRANCISCO, Calif. , ... AGN ), a leading global pharmaceutical company, and Oculeve, ... treatments for dry eye disease, today announced that they ... acquire Oculeve in an all-cash transaction.  Under the terms ... $125 million upfront payment and commercialization milestone payments related ...
(Date:7/6/2015)... -- China Information Technology, Inc. (the "Company" or "CNIT") ... platform, exchange, and big data solutions in ... its mobile app for Healthcare One Pass, ushering in ... devices. The Company jointly hosted the launch ceremony with ... Shenzhen News Net.   The mobile app for ...
(Date:7/4/2015)... BARCELONA , España, July 4, 2015 /PRNewswire/ ... SIR-Spheres® Y-90 a la quimioterapia de primera línea ... en el hígado (mCRC) extiende la supervivencia libre ... pacientes con cáncer colorrectal metastásico no resecable (mCRC) ... la mayor mejora en la supervivencia libre de ...
Breaking Medicine Technology:Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 2El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 3El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 5
... HILL, N.C., Aug. 24 TSI Healthcare, a local ... customized technology solutions for physician practices, was recognized for ... 100 Vendors" 2010 annual listing. TSI is ranked among ... including Microsoft® (#47), Dell™ (#2), NextGen Healthcare® (#29), 3M ...
... NacTel (North Atlantic Communications), a leading provider of ... and integrated a new state-of-the-art customer communications system ... the fastest growing durable medical equipment companies in ... set to serve its customers, and chose the ...
Cached Medicine Technology:TSI Healthcare Again Recognized in "Healthcare Informatics TOP 100" 2Drive Medical Equipment Chooses NacTel with ShoreTel as its Critical Communications Provider 2Drive Medical Equipment Chooses NacTel with ShoreTel as its Critical Communications Provider 3Drive Medical Equipment Chooses NacTel with ShoreTel as its Critical Communications Provider 4
(Date:7/7/2015)... ... July 07, 2015 , ... CSG ... have been selected by the Department of Vermont Health Access to provide Quality ... Information System (MMIS) and Integrated Contact Center System project. , Vermont is implementing ...
(Date:7/6/2015)... ... 2015 , ... Respected southern California personal injury attorney Fernando D. Vargas has ... attorney who has sharp legal skills as well as a superior commitment to client ... Martindale-Hubbell and a Top 10 Award from The National Academy of Personal Injury Attorneys ...
(Date:7/6/2015)... ... ... a report titled “ Female Hair Loss Needs to be Talked About, Shed Stigma, Experts ... the U.S. will suffer from thinning hair or hair loss . For these 30 million ... beauty queen, who was interviewed for the report began losing her hair at age 11 due ...
(Date:7/6/2015)... London, UK (PRWEB) , ... July 06, 2015 , ... ... 5.58 billion in 2014. It is expected to grow at a CAGR of over ... by 2021. , The growth is likely to be mainly spurred by an anticipated ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with the CHN ... same cancer. , “Receiving a cancer diagnosis is often the most traumatic experience ...
Breaking Medicine News(10 mins):Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 3Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... Former CBS Early Show Anchor, Jane Clayson Will Host Podcast, ... moms on the go, a new series of podcasts launched ... baby health, and,nutrition, as well as answers to the questions ... You -- Champion for Babies is a one-on-one interview,series hosted ...
... healthcare professionals from across Pennsylvania with substantial ... HARRISBURG, Pa., Sept. 11 The Pennsylvania,Patient Safety ... of infection control experts to help implement Act ... by Governor Ed Rendell in July to help ...
... PCMA: Time to Require E-Prescribing in Medicare, ... finds,dangerous drug side effects and deaths - particularly ... underscores the urgency for Congress to act,now to ... Management Association (PCMA) said today., "This study ...
... CHICAGO, Ill. The nuclear power industry is riding the ... of a low-carbon solution to our growing energy needs. ... role nuclear can realistically play, it is bound by ... still predominantly shaped by the marketplace. , Veteran ...
... prostate cancer among men taking the drug finasteride is ... not by the development of more high-grade cancers, according ... Journal of the National Cancer Institute . , ... long-term randomized trial of a possible drug to prevent ...
... at least some education beyond high school is associated with ... education levels were strongly associated with decreased cancer mortality among ... mortality for all groups was greatest between those with 12 ... 12 years. , Previous studies have found that death rates ...
Cached Medicine News:Health News:March of Dimes, Experts for Moms and Babies, Launches Podcast 2Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 2Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 3Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 4Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 5Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 6Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 7Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 8Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 9Health News:New Report: Dangerous Drug Side Effects and Deaths Doubled Since 1998... Seniors Hit Hardest 2Health News:Trade-offs reveal no clear favorites in alternative energy market 2Health News:Finasteride unlikely to induce high grade prostate cancers 2Health News:Finasteride unlikely to induce high grade prostate cancers 3Health News:Study links education to risk of cancer death 2Health News:Study links education to risk of cancer death 3
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. For newly born children. 10 mm internal diameter of the cornea ...
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. For newly born children. 10 mm internal diameter of the cornea ...
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. The classic Goldmann Glass....
This table provides the user with a moderatelypriced, yet fully versatile, electric table which will accept most HAAG-STREIT instruments as well as many of those from other ophthalmic manufacturers....
Medicine Products: